share_log

寶光實業:股份發行人的證券變動月報表

STELUX HOLDINGS: Monthly Return of Equity Issuer on Movements in Securities

香港交易所 ·  Jan 31 22:30
Summary by Moomoo AI
寶光實業(國際)有限公司於2024年1月31日向香港交易及結算所有限公司提交了新的證券變動月報表。報告顯示,公司的法定/註冊股本及已發行股份在該月份內無變動,維持在1,600,000,000股,每股面值0.1港元,總額160,000,000港元。此外,報告中確認了公司在該月份內發行的證券已獲得董事會的正式授權,並且已履行所有上市前的法定要求。報告由公司董事廖晶薇女士於2024年2月1日呈交。
寶光實業(國際)有限公司於2024年1月31日向香港交易及結算所有限公司提交了新的證券變動月報表。報告顯示,公司的法定/註冊股本及已發行股份在該月份內無變動,維持在1,600,000,000股,每股面值0.1港元,總額160,000,000港元。此外,報告中確認了公司在該月份內發行的證券已獲得董事會的正式授權,並且已履行所有上市前的法定要求。報告由公司董事廖晶薇女士於2024年2月1日呈交。
Po Kwong Industrial (International) Limited filed a new Monthly Securities Change Report with Hong Kong Trading and Settlement Limited on 31 January 2024. The report shows that the company's regulated/registered share capital and issued shares remained unchanged during the month at 1,600,000,000 shares with a face value of HK$0.1 per share for a total of HK$160,000,000. In addition, the report confirms that the securities issued by the company during the month have been formally authorized by the Board of Directors and have met all pre-listing regulatory requirements. The report was submitted by Ms. LIU Jingwei, Director of the Company, on February 1, 2024.
Po Kwong Industrial (International) Limited filed a new Monthly Securities Change Report with Hong Kong Trading and Settlement Limited on 31 January 2024. The report shows that the company's regulated/registered share capital and issued shares remained unchanged during the month at 1,600,000,000 shares with a face value of HK$0.1 per share for a total of HK$160,000,000. In addition, the report confirms that the securities issued by the company during the month have been formally authorized by the Board of Directors and have met all pre-listing regulatory requirements. The report was submitted by Ms. LIU Jingwei, Director of the Company, on February 1, 2024.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more